Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iMMagine-6: Anitocabtagene Autoleucel vs Auto-SCT in Newly Diagnosed Multiple Myeloma
NCT07903506Phase 3Not yet recruiting
- Sponsor
- Kite Pharma
- Start
- Feb 2027
- Primary completion
- Mar 2039
01
Overview
A Phase 3 trial of anitocabtagene autoleucel in multiple myeloma (MM), sponsored by Kite Pharma. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
anitocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07903506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903506.